Table 1. Baseline characteristics of patients, stratified by NLR, PLR, and LMR.
| Characteristic | Total | NLR | PLR | LMR | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| <3.89 | ≥3.89 | p-value | <218 | ≥218 | p-value | >1.8 | ≤1.8 | p-value | ||
| Age (y) | 0.019* | 0.164 | 0.008* | |||||||
| <70 | 82 (36.3) | 69 (40.6) | 13 (23.2) | 71 (38.4) | 11 (26.8) | 76 (40.0) | 6 (16.7) | |||
| ≥70 | 144 (63.7) | 101 (59.4) | 43 (76.8) | 114 (61.6) | 30 (73.2) | 114 (60.0) | 30 (83.3) | |||
| Sex | 0.490 | 0.521 | 0.903 | |||||||
| Male | 174 (77.0) | 129 (75.9) | 45 (80.4) | 144 (77.8) | 30 (73.2) | 146 (76.8) | 28 (77.8) | |||
| Female | 52 (23.0) | 41 (24.1) | 11 (19.6) | 41 (22.2) | 11 (26.8) | 44 (23.2) | 8 (22.2) | |||
| Tumour grade | 0.036* | 0.015* | 0.003* | |||||||
| G1/G2 | 132 (58.4) | 106 (62.4) | 26 (46.4) | 115 (62.2) | 17 (41.5) | 119 (62.6) | 13 (36.1) | |||
| G3 | 94 (41.6) | 64 (37.6) | 30 (53.6) | 70 (37.8) | 24 (58.5) | 71 (37.4) | 23 (63.9) | |||
| Tumour stage | 0.000* | 0.000* | 0.000* | |||||||
| Ta/T1 | 175 (77.4) | 146 (85.9) | 29 (51.8) | 153 (82.7) | 22 (53.7) | 156 (82.1) | 19 (52.8) | |||
| T2+ | 51 (22.6) | 24 (14.1) | 27 (48.8) | 32 (17.3) | 19 (46.3) | 34 (17.9) | 17 (47.2) | |||
| Tumour size (cm) | 0.029* | 0.000* | 0.002* | |||||||
| <3 (small) | 133 (58.8) | 107 (62.9) | 26 (46.4) | 119 (64.3) | 14 (34.1) | 120 (63.2) | 13 (36.1) | |||
| ≥3 (large) | 93 (41.9) | 63 (37.1) | 30 (53.6) | 66 (35.7) | 27 (65.9) | 70 (36.8) | 23 (63.9) | |||
| Multiplicity | 0.048* | 0.011* | 0.627 | |||||||
| Solitary | 149 (65.9) | 106 (62.4) | 43 (76.8) | 115 (62.2) | 34 (82.9) | 124 (65.3) | 25 (69.4) | |||
| Multiple | 77 (34.1) | 64 (37.6) | 13 (23.2) | 70 (37.8) | 7 (17.1) | 66 (34.7) | 11 (30.6) | |||
Values are presented as number (%).
NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio.
*p<0.05, statistically significant difference.